Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol
(THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist
Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.